The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Katakami, Naoto; Mita, Tomoya; Yoshii, Hidenori; Shiraiwa, Toshihiko; Yasuda, Tetsuyuki; Okada, Yosuke; Torimoto, Keiichi; Umayahara, Yutaka; Kaneto, Hideaki; Osonoi, Takeshi; Yamamoto, Tohru; Kuribayashi, Nobuichi; Maeda, Kazuhisa; Yokoyama, Hiroyuki; Kosugi, Ken’ichirou; Ohtoshi, Kentaro; Hayashi, Isao; Sumitani, Satoru; Tsugawa, Mamiko; Ryomoto, Kayoko; Taki, Hideki; Nakamura, Tadashi; Kawashima, Seiichiro; Sato, Yasunori; Watada, Hirotaka; Shimomura, Iichiro; Investigators, Utopia Study

doi:10.1007/s13300-021-01125-8

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the UTOPIA study of clinical cases revealed that TOFO exhibits exceptional therapeutic effects on atherosclerosis. 42 , 43 Therefore, the combination therapy with TOFO may represent an optimal treatment strategy for diabetes, encompassing measures against atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

Nomura¹,

Shouzu²,

Taniura³

et al. 2023

CPAA

View full text Add to dashboard Cite

Purpose In people with type 2 diabetes mellitus (T2DM), both glucose metabolism abnormalities and atherosclerosis risk are significant concerns. This study aims to investigate the effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin (TOFO) and the dipeptidyl peptidase-4 inhibitor anagliptin (ANA) on markers of glucose metabolism and atherosclerosis when administered individually or in combination. Methods Fifty T2DM patients were divided into two groups (receiving either TOFO or ANA monotherapy) and observed for 12 weeks (observation points: 0 and 12 weeks). The TOFO and ANA groups were then further treated with ANA and TOFO, respectively, and the patients were observed for an additional 36 weeks (observation points: 24 and 48 weeks). Therapeutic effects and various biomarkers were compared between the two groups at the observation points. Results Combination therapy led to significant improvements in HbA1c levels and atherosclerosis markers. Additionally, the TOFO pretreatment group exhibited significant reductions in sLOX-1 and IL-6 levels. Conclusion The increase in sLOX-1 and IL-6 levels, which indicates the response of scavenger receptors to oxidized low-density lipoproteins in people with T2DM, is mitigated following TOFO and ANA combination therapy. TOFO alone or in combination with ANA may be beneficial for preventing atherosclerosis development in people with T2DM, in addition to its effect on improving HbA1c levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

Nomura¹,

Shouzu²,

Taniura³

et al. 2023

CPAA

View full text Add to dashboard Cite

show abstract

“…PWV response can often occur independent of systolic BP levels. 4,5 Therefore, a lingering question persists: Could arterial stiffness be a more significant risk factor for CSVD progression and a more appropriate treatment target than hypertension in stroke-free individuals?…”

Section: See Related Article P 2814mentioning

confidence: 99%

Arterial Stiffness as the Prevailing Risk Factor for Cerebral Small Vessel Disease in Stroke-Free Individuals

Noriega de la Colina,

Lioutas

2023

Stroke

View full text Add to dashboard Cite

“…In addition to its effect on glycemic control, tofogliflozin improves high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels, decreases body weight and blood pressure, and elevates circulating adiponectin levels [ 11 ]. We previously investigated the effect of tofogliflozin on carotid artery intima-media thickness (IMT) [ 12 ], which is a marker of atherosclerosis [ 13 ], arterial stiffness [ 14 ], and patients’ quality of life (QOL) [ 15 ], in the “Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)” trial. Although tofogliflozin did not delay the progression of IMT thickening, it significantly improved glycemic control, body weight, body mass index (BMI), abdominal circumference, systolic blood pressure, HDL-C, arterial stiffness, and treatment-related QOL [ 12 , 14 , 15 ] during the 2-year intervention period.…”

Section: Introductionmentioning

confidence: 99%

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Katakami¹,

Mita²,

Yoshii³

et al. 2023

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of cardiovascular disease. Methods This was a prospective observational 2-year extension study of the “Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)” trial, a 2-year randomized intervention study. The primary endpoints represented changes in the carotid intima-media thickness (IMT). Secondary endpoints included brachial-ankle pulse wave velocity (baPWV) and biomarkers for glucose metabolism, lipid metabolism, renal function, and cardiovascular risks. Results The mean IMT of the common carotid artery (IMT-CCA) significantly decreased in both the tofogliflozin (− 0.067 mm, standard error 0.009, p < 0.001) and conventional treatment groups (− 0.080 mm, SE 0.009, p < 0.001) throughout the follow-up period; however, no significant intergroup differences in the changes (0.013 mm, 95% confidence interval (CI) − 0.012 to 0.037, p = 0.32) were observed in a mixed-effects model for repeated measures. baPWV significantly increased in the conventional treatment group (82.7 ± 210.3 cm/s, p = 0.008) but not in the tofogliflozin group (− 17.5 ± 221.3 cm/s, p = 0.54), resulting in a significant intergroup difference in changes (− 100.2 cm/s, 95% CI − 182.8 to − 17.5, p = 0.018). Compared to the conventional treatment group, tofogliflozin significantly improved the hemoglobin A1c and high-density lipoprotein cholesterol levels, body mass index, abdominal circumference, and systolic blood pressure. The frequencies of total and serious adverse events did not vary significantly between the groups. Conclusions Tofogliflozin was not associated with improved inhibition of carotid wall thickening but exerted long-term positive effects on various cardiovascular risk factors and baPWV while showing a good safety profile.

show abstract

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus

Cited by 5 publications

References 32 publications

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

Arterial Stiffness as the Prevailing Risk Factor for Cerebral Small Vessel Disease in Stroke-Free Individuals

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Contact Info

Product

Resources

About